Leighann Forbes<\/b><\/strong><\/p>\n<\/div>\n \u201cRelapses can disrupt stability, undermine functioning, and often trigger disruptive episodes such as psychosis or hallucinations that can derail daily life for patients and their loved ones,\u201d she said. <\/p>\n
Adults with schizophrenia experience an average of nine relapse episodes per 6-year period, according to the release. <\/p>\n
\u201cEach relapse can contribute to deterioration in symptoms, cognition, functioning, quality of life and life expectancy,\u201d Forbes said. \u201cThat\u2019s why managing relapse risk is a critical goal in long-term disease management.\u201d<\/p>\n
However, physicians often focus on symptoms to reduce risks for relapse instead of treating the relapse itself, Forbes said. <\/p>\n
\u201cA comprehensive treatment plan, which could include medication and psychosocial services, can help reduce the risk of relapse for adults with schizophrenia,\u201d she said. \u201cAddressing this risk can help patients maintain functioning, reduce caregiver and societal strain and break the cycle of repeated hospitalizations.\u201d<\/p>\n
In a phase 3, double-blind, randomized withdrawal trial, Johnson & Johnson said that daily oral 42 mg doses of Caplyta (lumateperone) significantly extended time to relapse compared with placebo over 26 weeks, with risks for relapse falling by 63%. <\/p>\n
Also, 84% of patients on Caplyta did not experience a relapse for 6 months, with significant delays in time to treatment discontinuation due to relapse and all other causes. <\/p>\n
Johnson & Johnson further said no new safety concerns were identified during this trial and that its safety profile was consistent with previous data. Headache was the most common adverse event related to treatment. <\/p>\n
\u201cTogether, these data reinforce Caplyta as a safe and effective treatment option for adults living with schizophrenia,\u201d Forbes told Healio. \u201cCaplyta can be taken at any time of day and does not require titration, meaning patients can start treatment at the effective dose for them.\u201d<\/p>\n
Caplyta was previously approved for adults with major depressive disorder, schizophrenia and depressive episodes associated with bipolar I or II disorder in conjunction with antidepressants, lithium or valproate or as a monotherapy. <\/p>\n
\u201cCaplyta can be prescribed to patients who have experienced relapse,\u201d Forbes said. <\/p>\n
For more information:<\/b> <\/p>\n
Leighann Forbes,<\/b> MS, PhD<\/b>, <\/b>can be reached at neurology@healio.com.<\/p>\n\n
\n
Sources\/Disclosures<\/h3>\n Source: <\/h2>\n
\n
Disclosures: <\/strong>
<\/p>\n
\n
\n
<\/p>\n
Ask a clinical question<\/strong> and tap into Healio AI’s knowledge<\/strong> base.<\/p>\n
<\/p>\nPubMed, enrolling\/recruiting trials, guidelines<\/li>\n
<\/p>\n
Clinical Guidance, Healio CME, FDA news<\/li>\n
<\/p>\n
Healio’s exclusive daily news coverage of clinical data<\/li>\n
\n <\/ul>\n
Learn more<\/button>\n <\/div>\n<\/div>\n